References
- A predictive model for aggressive non-Hodgkin lymphoma. The International Non-Hodgkin lymphoma prognostic factors project. N Engl J Med 1993; 329: 987–994
- Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004; 104: 1258–1265
- Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008; 111: 558–565
- Hoster E, Dreyling M, Unterhalt M. Statistical power and validation of the MIPI. Blood 2008; 112: 2583–2584
- Terol M J, Teruel A I, Amat P, et al. Validation of the new prognostic index (MIPI) in mantle cell lymphoma: a single institution experience [abstract]. Ann Oncol 2008; 19(4)439
- Salek D, Vasova I, Pytlik R, et al. Mantle cell lymphoma international prognostic score is valid and confirmed in unselected cohort of patients treated in rituximab era [abstract]. Blood 2008; 112: 3745
- Pan L, Guthrie K A, Till B G, et al. The mantle cell lymphoma international prognostic index (MIPI) at diagnosis is associated with survival of mantle cell lymphoma patients undergoing autologous hematopoietic stem cell transplantation [abstract]. Blood 2008; 112: 1143
- Shah J J, Fayad L, Romaguera J. Mantle Cell International Prognostic Index (MIPI) not prognostic after R-hyper-CVAD. Blood 2008; 112: 2583
- Romaguera J E, Fayad L, Rodriguez M A, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005; 23: 7013–7023